tbuckley/cabot-search huggingface dataset:
Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)
Authors: T.K. Owonikoko, K. Nackaerts, T. Csoszi, G. Ostoros, C. Baik, Z. Mark, E. Sheldon-Waniga, D. Huebner, E.J. Leonard, D.R. Spigel
Journal: Annals of Oncology (2016)
GENT-53. SELF-ORGANIZATION OF GLIOMAS: GENETIC RODENT MODELS, GENOMIC NETWORKS, AND MATHEMATICAL MODELING
Authors: Pedro Lowenstein, Sebastien Motsch, Viveka Nand Yadav, Daniel Zamler, Andrea Comba, Carl Koschmann, Felipe J Nunez, Alexandra Calinescu, Neha Kamran, Marta Dzaman, Maria G. Castro
Journal: Neuro-Oncology (2016)

The existence of large scale organization in gliomas remains unknown. We here demonstrate that gliomas are indeed self-organized. We do so by uncovering the cellular, genomic, and mathematical networks that underlie glioma self-organization and aggressive behavior. Glioma self-organization was studied in genetically induced gliomas using the Sleeping Beauty Transposase system expressing/down-modulating N-Ras, large T ag from SV40, TP53, PDGF, ATRX, and IDH1-R132H. We discovered the existence of onco-streams within gliomas, the glioma equivalent of self-organizing flocks of birds. Onco-streams are 10-20 glioma cells wide, of variable length, formed by fusiform cells, and are distributed throughout tumors. Onco-streams participate in glioma growth, invasion, and lethality. Onco-streams play various roles: they enhance migration of slower moving glioma stem cells, and block immune cell invasion of gliomas. Both in human and in rodent gliomas the prevalence of onco-streams correlates positively with tumor aggressiveness. Secondly, we modeled gliomas’ onco-streams using agent based computational modeling. Cellular interactions in our model were exhaustively studied using numerical investigations of our agent- based model. Our model predicts that changes in cell shape affect the population behavior of glioma cells, induce the formation of onco-streams, and thereby increase tumor aggressiveness. These predictions are now being tested experimentally. Thirdly, we analyzed the genomic structure of gliomas’ self-organization. Utilizing RNA-seq and bioinformatic analyses we uncovered a gene expression network that underlies onco-stream formation, and aggressive glioma behavior. One of the most highly connected gene nodes was selected for inhibition. Specific pharmacological and genetic targeting of this network demonstrated strong inhibitory effects only of the most malignant glioma models, as predicted by our analysis. We conclude that gliomas are self-organizing structures. This is supported by experimental, mathematical, and genomic studies. Finally, this approach will lead to the discovery of hitherto unsuspected essential therapeutic targets as is illustrated herein.
P21.08 Stereotactic biopsy in elderly patients: risk assessment and impact on treatment decision
Authors: S. G. Kellermann, C. A. Hamisch, V. Hafkemeyer, D. Rueß, S. J. Grau, M. I. Ruge
Journal: Neuro-Oncology (2016)

AbstractObjective:To evaluate feasibility and risk profile of stereotactic biopsy (SB) in elderly patients and to analyse its impact upon treatment decision.Methods:In this single center retrospective analysis we identified all patients aged ≥70 years receiving SB in a defined period between January 2005 and December 2015. We documented age, gender, Karnofsky Performance Status (KPS), histology, co-morbidity (by CHA2DS2-VASc Score) and use of anticoagulation. We then scrutinized feasibility, diagnostic yield, procedural complications (mortality, transient and permanent morbidity), time as an in-patient and the overall therapeutic consequence. For correlational analysis regarding outcome Chi-Square, Mann-Whitney rank sum test and binary regression were used.Results:Two hundred and thirty patients were included. In 229 patients SB was successfully performed. Median age was 74 (70–87) years, gender distribution was male in 56.1% and median preoperative KPS was 80 (30–100). Pathological diagnosis was conclusive in 96.1% revealing neoplastic lesions in 91.7% (high-grade glioma 62.6%, lymphoma 18.3%, metastasis 4.8%, low-grade glioma 3.0% and other tumors 3.0%) and non-neoplastic lesions in 4.4%. Median CHA2DS2-VASc Score was 4 (1–9); 29.6% received anticoagulation and median stay as an inpatient was 8 (2–29) days.Procedure-related mortality was 0.4%, transient morbidity was seen in 19 patients (8.3%) and permanent morbidity in eight patients (3.5%; aggravation of preoperative symptoms (n=7); decreased level of consciousness (n=1)). Adjuvant disease specific therapy was initiated in 171/230 (74.3%) patients.Complication rate was not associated with any above-mentioned parameters. Decision against disease-specific therapy was not influenced by age but only by preoperative KPS <70 (p<0.001).Conclusion:These data demonstrate that stereotactic biopsy in elderly patients is feasible, safe and offers a high diagnostic yield. Thus, it can be offered to elderly patients ≥ 70 years in an independent functional status (KPS≥70) with unclear cerebral lesions to submit disease specific therapy irrespective of localization, medical history or anticoagulant medication.
Dynamics of the HER2 receptor in esophageal adenocarcinoma: New opportunities for targeted therapy
Authors: A. Creemers, E.A. Ebbing, G.K.J. Hooijer, A.R.A. Jibodh-Mulder, S.S. Gisbertz, M.G.H. van Oijen, M. Ivan Berge Henegouwen, M.F. Bijlsma, S.L. Meijer, H.W.M. van Laarhoven
Journal: Annals of Oncology (2016)
Is the 315/P Tumor an IgA Lymphoma?: Reply
Authors: Howard M. Gebel, Johnna R. Autry, James W. Rohrer, Richard G. Lynch
Journal: JNCI Journal of the National Cancer Institute (1979)

Journal Article Is the 315/P Tumor an IgA Lymphoma?: Reply Get access Howard M. Gebel, Howard M. Gebel Department of Pathology Washington University School of MedicineSt. Louis, Missouri 63110 Search for other works by this author on: Oxford Academic PubMed Google Scholar Johnna R. Autry, Johnna R. Autry Department of Pathology Washington University School of MedicineSt. Louis, Missouri 63110 Search for other works by this author on: Oxford Academic PubMed Google Scholar James W. Rohrer, James W. Rohrer Department of Pathology Washington University School of MedicineSt. Louis, Missouri 63110 Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard G. Lynch Richard G. Lynch Department of Pathology Washington University School of MedicineSt. Louis, Missouri 63110 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 63, Issue 3, September 1979, Pages 538–539, https://doi.org/10.1093/jnci/63.3.538-a Published: 01 September 1979
Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,
Authors: Simona Soverini, Caterina De Benedittis, Alessandra Gnani, Ilaria Iacobucci, Domenico Russo, Federica Cattina, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Antonella Vitale, Loredana Elia, Robin Foà, Francesca Palandri, Annalisa Lonetti, Maria Teresa Bochicchio, Sandra Durante, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2011)
MPTH-21. MOLECULAR CHARACTERIZATION REVEALS NF1 LOSS AND FGFR1 ACTIVATING MUTATIONS IN PEDIATRIC SPINAL OLIGODENDROGLIOMA
Authors: Amy K. Bruzek, Andrew Zureick, Sriram Venneti, Paul McKeever, Hugh J.L. Garton, Patricia Robertson, Rajen Mody, Carl Koschmann
Journal: Neuro-Oncology (2016)

Spinal anaplastic oligodendroglioma is a rare and aggressive tumor. Despite maximal treatment with surgical resection, radiation therapy, and chemotherapy, survival is less than 50% at 5 years. Spinal oligodendroglioma is generally seen in older patients, but it has also been reported in children. Little is known of the molecular drivers of this tumor. We present a nine-year-old girl who was diagnosed at age three with an anaplastic ­oligodendroglioma of the cervical spine. She underwent subtotal resection followed by cyclic temozolomide for 16 months. She developed local recurrent disease at age eight and again underwent subtotal resection. At recurrence, tumor pathology showed Grade III oligodendroglioma, 1p/19q co-deletion negative, MGMT unmethylated, IDH mutation negative. We performed exome (tumor and germline DNA) and transcriptome (tumor RNA) sequencing on her recurrent tumor. Sequencing revealed a point mutation and three small deletions, all somatic, in neurofibromin 1 (NF1). She had no evidence of germline NF1 alterations, skin lesions, or a family history suggestive of familial NF1. We also observed two activating missense somatic mutations adjacent to tyrosine phosphorylation sites Y653 and Y654 on fibroblast growth factor receptor 1 (FGFR1). After resection, she underwent focal proton irradiation, and subsequently developed acute radiation necrosis, which has responded well to treatment with steroids and bevacizumab. Results of her tumor sequencing were discussed in a CNS precision medicine tumor board teleconferenced with clinicians at multiple children’s hospitals, which made recommendation to consider adjuvant therapy with an FGFR inhibitor (for FGFR1 mutations) and/or a MEK inhibitor (for NF1 loss-of-function). We will consider these therapies with family after further resolution of her radiation necrosis. In summary, we provide genomic data on a case of pediatric spinal anaplastic oligodendroglioma. This data allowed us to examine potential personalized therapies for this patient, and expose molecular drivers that may be involved in similar cases.
Improvement of Thrombolysis by Rivaroxaban, An Anti Xa Inhibitor. Potential Therapeutic Importance in Patients with Thrombosis
Authors: Remi Varin, Shasultan Mirshahi, Pehzman Mirshahi, Li Lu-Hong, Gerald Kierzek, Jean-Francois Vigneau, Jean-Pierre Marie, Elisabeth Perzborn, Massoud Mirshahi, Claudine Soria, Jeannette Soria
Journal: Blood (2008)
New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias
Journal: Cardiovascular Research (2001)

Cardiac arrhythmias complicate many diseases affecting the heart and the circulation, and incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design in mechanism-specific and disease-specific fashion facilitates targeting of therapy via the methods of molecular, structural and translational biology. Additional approaches, employing similar drug design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies.
Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).
Authors: Stefan Faderl, Deborah A. Thomas, Farhad Ravandi, Guillermo Garcia-Manero, Miloslav Beran, Michael Rytting, Charles A. Koller, Srdan Verstovsek, Gautam Borthakur, Michael Andreeff, Steve Kornblau, Susan O’Brien, Khanh Vu, Monica Kwari, Jennie Bretz, Hagop M. Kantarjian
Journal: Blood (2007)
RTHP-38. IMPROVING ACCESS TO RADIATION: A RETROSPECTIVE ANALYSIS TO IDENTIFY BARRIERS TO TREATMENT AMONG HIGH GRADE GLIOMA PATIENTS IN THE BRONX
Authors: Juhi Purswani, Nina Massad, Patrick Lasala, Nitin Ohri, Mary Welch
Journal: Neuro-Oncology (2016)

Racial and ethnic minorities and the economically disadvantaged have been shown to receive lower quality healthcare, but few studies have evaluated how differences across socioeconomic variables impact neuro-oncological care. Montefiore Medical Center (MMC) serves one of the most diverse populations in the nation and its catchment area encompasses the highest percentage of uninsured patients in New York. As part of a quality improvement (QI) initiative established to identify and minimize barriers to treatment among MMC’s brain tumor population, we retrospectively identified patients over age 20 diagnosed with a WHO Grade III or IV glioma and treated at our institution between 2005 and 2015. Patient characteristics were summarized with descriptive statistics. Logistic regression was used to identify variables associated with initiation of radiation treatment (RT). Odds ratios (OR) and 95% confidence intervals (CIs) were calculated for the effect of insurance status, ethnicity (white, Hispanic, black, other), English proficiency, gender, age <50 and performance status <60. Two hundred and thirty-nine patients were included in the analysis. Median age was 62 (range 20-97); 58% were men. Patients self-identified as black (24%), Hispanic (31%), white (36%) and other (9%). Twenty-five percent lacked proficiency in English and 22% were Medicaid recipients. Complete data on initial treatment was available for 222 patients. Of these, 181 (82%) initiated RT; the remainder did not. Men (OR 2.5; CI 1.2-5.1), those with proficiency in English (OR 2.4; CI 1.13-5) and KPS >60 (OR 2.9; CI 1.2-6.8) were more likely to initiate treatment. Neither insurance coverage nor race had an impact on RT in our population. Among MMC’s diverse and historically under-represented patients, women and non-English speakers were less likely to initiate RT as compared to men and English speakers. Further QI initiatives are needed to better understand these differences and improve access for all.
A study of fluorophore labeled cell-permeable peptides in cancer research
Authors: Koji Kono, Hideki Amemiya, Hidemitsu Sugai, Hideki Fujii
Journal: Cancer Research (2004)

4387  Background Patients with gastric cancers producing alpha-fetoprotein (AFP) were reported to have a poor prognosis with high rates of liver metastasis. The purpose of the present study was to clarify the clinicopathological and molecular features of AFP-producing gastric cancers. Methods In 27 of the 29 cases with elevated preoperative serum AFP levels among a total of 974 primary gastric cancers, AFP production was confirmed in gastric cancer cells by immunohistochemistry. Twenty-seven patients with AFP-producing gastric cancers [AFP(+)] and 27 patients with stage-matched gastric cancers that did not produce AFP [AFP(-)] were evaluated for c-Met, HGF, VEGF and VEGF-C expression and vessel density using immunohistochemical analysis. Furthermore, we established an AFP-producing gastric cancer cell line (AME-1) and characterized its molecular feature. Results The survival rate of the AFP(+) group was significantly worse than that of the stage-matched AFP(-) group (p
The Atypical Gtpase Rhou Lies Downstream IL6/STAT3 and Regulates Myeloma Plasma Cells Adhesion/Motility
Authors: Sara Nunes Canovas, Marilena Carrino, Sabrina Manni, Laura Quotti Tubi, Martina Manzoni, Gregorio Barilà, Livio Trentin, Renato Zambello, Antonino Neri, Gianpietro Semenzato, Francesco Piazza
Journal: Blood (2016)
P20.02 Graphene in neurosurgery: a potential and innovative strategy in the treatment of cerebral gliomas
Authors: M. Caffo, R. V. Abbritti, G. Caruso, V. Barresi, L. Minutoli, A. Germanò, F. Tomasello
Journal: Neuro-Oncology (2016)

AbstractGliomas account for around 45% of primary brain tumors. The treatment of malignant gliomas depend on the person’s age, the type of tumor, and the location of the tumor. These tumors tend to grow into the normal brain tissue, with the result that complete surgical removal can be very difficult to reach. Current therapy is unsatisfactory due to low therapeutic efficiency and strong systemic side effects of chemo- and/or radiotherapy protocols.The standard protocol includes maximal surgical resection with postoperative combination of radiation therapy with concomitant and adjuvant chemotherapy. Surgical treatment represents the first initial treatment. However, in spite of the recent innovations in surgical techniques, including intraoperative mapping, we only got a slight improvement of the prognosis. Additionally, radiation therapy is also used to treat gliomas in locations where surgery is not safe and for recurrent gliomas. Chemotherapy is recommended for some high-grade gliomas after surgery and radiation therapy. The presence of the blood-brain barrier impedes the passage of a large number of molecules into the brain. However, most of the current drugs show limited solubility, high toxicity and have a nonspecific delivery. Targeted drugs delivery systems can convey drugs more effectively and increase patient compliance. Recent advances in molecular and biological techniques have evidence new glioma-associated biomarkers and their implications for gliomas progression. The possibility to block contemporary more pathways into glioma by molecular-based targeted approaches, using a nanocarrier loaded with anticancer agent, represent a promising therapeutic strategy.Nanomedicine holds great promise for evolutionizing medical treatments, imaging and drug delivery. Nanoparticles provide better penetration of therapeutic agents and a reduced risk in comparison to conventional treatments. By using nanotechnology it is possible to deliver the drug to the targeted tissue across the blood-brain barrier and release the drug at a controlled rate. Graphene is a versatile two-dimensional nanomaterial thanks to its unique physical and chemical characteristics. Numerous experimental studies have also been made to employ graphene as a vehicle for antitumoral therapies. We think that, using the intrinsic capacity of graphene, should be very interesting to structure a new nanoparticle-based molecular approach against molecular targets, contemporary. In our laboratories, we are trying to create a carrier loaded with an antisense molecule against hypoxic ischemic factor-1α (HIF-1 α) and IL-8. However, there is currently no deﬁnitive study regarding the therapeutic potentialities or risks of graphene nanoparticles. They offer many opportunities for cancer therapy, but their interaction with biological tissues has not yet been fully elucidated.
P06.08 Thrombospondin-1 is a master regulator of glioblastoma vascularization and infiltration
Authors: T. Daubon, C. Leon, K. Clarke, F. Falciani, A. Bikfalvi, R. Bjerkvig
Journal: Neuro-Oncology (2016)

CONCLUSION: Compared to NB, ATF5 is significantly overexpressed on mRNA level in LGA and GBM independently of tumor growth patterns.Since inhibition of ATF5 might lead to the selective death of glioma cells, but not of non-tumor cells, it might serve as a potential ubiquitous therapeutic target in astrocytic tumors, independently of WHO grading or growth pattern.
Local Control of Ocular Adnexal Lympho-Proliferative Disorders (OALD): Similar Outcomes in MALT and Non-MALT Histologies
Authors: Binod Dhakal, Sridevi Ramalingam, Jamie Shuff, Narendranath Epperla, Lisa Rein, Anjishnu Banerjee, Malika Siker, Paul R. Hosking, Parameswaran Hari, Anita D'Souza, Ehab Atallah, Beth Erisckson, Timothy S. Fenske, Mehdi Hamadani
Journal: Blood (2015)
Combined Use of Interim Positron Emission Tomography Scans and Serum Soluble Interleukin-2 Receptor Values Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma
Authors: Yotaro Ochi, Nobuhiko Yamauchi, Yusuke Koba, Yasuhiro Kazuma, Yosuke Nagahata, Yuichiro Ono, Nobuhiro Hiramoto, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Megumu Hino, Yukihiro Imai, Takayuki Ishikawa
Journal: Blood (2014)
Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease
Authors: F. Rivera, M. Peeters, J.-Y. Douillard, J. Taieb, R. Koukakis, G. Demonty, S. Siena
Journal: Annals of Oncology (2016)
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
Authors: Y. Loriot, J.E. Rosenberg, T.B. Powles, A. Necchi, S. Hussain, R. Morales, M. Retz, G. Niegisch, I. Duran, C. Theodore, J.L. Perez-Gracia, E. Grande Pulido, A. Thåström, B. Danner, S. Mariathasan, O. Abidoye, M. van der Heijden
Journal: Annals of Oncology (2016)
Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia
Authors: Cihangir Duy, Daniel Nowak, Lars Klemm, Rahul Nahar, Carina Ng, Emily Elliott, Wolf-Karsten Hofmann, Nora Heisterkamp, Clifford A. Lowell, Phillip Koeffler, Markus Muschen
Journal: Blood (2010)
Two Cases of Tumor Lysis Syndrome in Solid Tumors
Authors: Mamika Nishii, Shinsuke Funakoshi, Keiichiro Saegusa, Ryohei Kishino, Gen Sakai, Atsushi Nakazawa, Yutaka Shimoyama, Nobuhiro Tsukada, Kiyoshi Mukai, Shigemichi Hirose
Journal: Annals of Oncology (2016)
Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival
Authors: Matthew J Maurer, James Cerhan, Jerry A Katzmann, Brian Link, Ivana N Micallef, Joseph Colgan, Thomas M. Habermann, David James Inwards, Svetomir Markovic, Stephen M. Ansell, Luis Porrata, Patrick B Johnston, Grzegorz S. Nowakowski, Carrie A Thompson, Mamta Gupta, Sergei I Syrbu, Paul Kurtin, William Macon, Thomas E. Witzig
Journal: Blood (2010)
Ph’-Positive (Ph’+) Chronic Myeloid Leukemia (CML) Presenting as Ph’+ T-Lymphoblastic Lymphoma (LL) Resistant to High-Dose Chemotherapy and Gleevec.
Authors: Lorenzo Falchi, Giorgia Desantis, Fabrizio Liberati, Roberta Pace, Maria G. Morandi, Patrizia Scaravaglio, Giuseppe Saglio, Anna M. Liberati
Journal: Blood (2005)
Molecular Alterations in Refractory Acute Myeloid Leukemia and Persistent Preleukemic Lesions Are Disclosed Using Mesenchymal Stromal Cells As Germline Control
Authors: Martin Neumann, Sebastian Vosberg, Eva Kristin Von Der Heide, Cornelia Schlee, Jutta Ortiz Tanchez, Konstandina Isaakidis, Liliana H. Mochmann, Lars R. Fransecky, Alexander Graf, Stefan Krebs, Helmut Blum, Philipp A. Greif, Claudia D Baldus
Journal: Blood (2015)
Report of NCI Ad Hoc Pathology Working Group To Review the Gross and Microscopic Findings of Breast Cancer Cases in the HIP Study (Health Insurance Plan of Greater New York)
Authors: Louis B. Thomas, Lauren V. Ackerman, Robert W. McDivitt, Thomas A.S. Hanson, Benjamin F. Benjamin F., Philip C. Prorok
Journal: JNCI Journal of the National Cancer Institute (1977)

Report of NCI Ad Hoc Pathology Working Group To Review the Gross and Microscopic Findings of Breast Cancer Cases in the HIP Study (Health Insurance Plan of Greater New York) Get access Louis B. Thomas, Louis B. Thomas Chairman Search for other works by this author on: Oxford Academic PubMed Google Scholar Lauren V. Ackerman, Lauren V. Ackerman Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert W. McDivitt, Robert W. McDivitt Search for other works by this author on: Oxford Academic PubMed Google Scholar Thomas A.S. Hanson, Thomas A.S. Hanson Search for other works by this author on: Oxford Academic PubMed Google Scholar Benjamin F. Benjamin F., Benjamin F. Benjamin F. Search for other works by this author on: Oxford Academic PubMed Google Scholar Philip C. Prorok Philip C. Prorok Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 2, August 1977, Pages 497–541, https://doi.org/10.1093/jnci/59.2.495 Published: 01 August 1977